AdvantiGen Biosciences

AdvantiGen Biosciences is a small biotechnology company headquartered in Madison, Wisconsin. With a staff of four employees, the company generates approximately $2.5 million in annual revenue. AdvantiGen focuses on developing novel immunotherapy treatments for cancer. Their research centers around a newly discovered Immune-Checkpoint target on T-cells, a target identified through extensive discovery and validation efforts. Their ADVAN-1 monoclonal antibody (mAbs) program aims to modulate the interaction between this target and its ligands, effectively restoring the T-cell's ability to destroy cancer cells. AdvantiGen's research indicates that their novel target interacts with various cancer cell types, suggesting potential clinical applicability across a wide range of cancers. These include solid tumors like skin, kidney, breast, colorectal, lung, and liver cancers, as well as blood cancers such as T-cell lymphoma and AML. For further information, please visit AdvantiGen Biosciences' website at advantigenbio.com.